High expression of AlkB homolog 5 suppresses the progression of non-small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11
- PMID: 38642004
- DOI: 10.1002/tox.24272
High expression of AlkB homolog 5 suppresses the progression of non-small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11
Abstract
Objective: Non-small cell lung cancer (NSCLC) is a prevailing LC characterized by poor outcomes. AlkB homolog 5 (ALKBH5) functions as a tumor suppressor in several cancers. This study delved into the role of ALKBH5 in NSCLC development.
Methods: TCGA database predicted ALKBH5 expression in NSCLC patients. ALKBH5 levels in NSCLC and human bronchial epithelial cells were determined. pcDNA3.1-ALKBH5/NC, pcDNA3.1-SLC7A11/NC, and ferrostatin-1 were used to explore the interactions among ALKBH5, SLC7A11, and ferroptosis. SLC7A11 mRNA and its protein levels were measured by RT-qPCR and Western blot. Cell viability, apoptosis, migration, and invasion were assessed by CCK-8, flow cytometry, and Transwell. Total N6-methyladenosine (m6A) quantification and its enrichment on SLC7A11 mRNA were determined, followed by the observation of Ki67, ALKBH5 and SLC7A11-positive cell numbers. Glutathione (GSH), lipid reactive oxygen species (lipid-ROS), malondialdehyde (MDA), and iron ion contents were determined. Animal experiments further analyzed the role of ALKBH5 in tumor development and glutathione peroxidase 4 (GPX4) expression.
Results: Bioinformatics analysis revealed the lowly-expressed ALKBH5 in LC patients. ALKBH5 was downregulated in NSCLC cells and its upregulation repressed proliferation activity, invasion, and migration, and facilitated apoptosis. ALKBH5 upregulation decreased GSH, increased lipid-ROS, MDA, and iron ion contents, and downregulated SLC7A11 by reducing m6A modification. SLC7A11 upregulation partly annulled the effect of ALKBH5 overexpression on cell ferroptosis and malignant behaviors. In vivo assays elucidated the suppression of ALKBH5 upregulation on tumor development and GPX4 levels.
Conclusion: ALKBH5 upregulation downregulates SLC7A11 transcription by decreasing m6A modification, thus promoting NSCLC cell ferroptosis and ultimately repressing NSCLC progression.
Keywords: AlkB homolog 5; SLC7A11; ferroptosis; m6A; non‐small cell lung cancer.
© 2024 Wiley Periodicals LLC.
Similar articles
-
IGF2BP3 suppresses ferroptosis in lung adenocarcinoma by m6A-dependent regulation of TFAP2A to transcriptionally activate SLC7A11/GPX4.Mol Cell Biochem. 2025 Apr;480(4):2361-2375. doi: 10.1007/s11010-024-05068-z. Epub 2024 Jul 18. Mol Cell Biochem. 2025. PMID: 39026029
-
PRKAA2 Promotes Tumor Growth and Inhibits Ferroptosis through SLC7A11/GSH/GPX4 Pathway in Non-Small Cell Lung Cancer.Biotechnol Appl Biochem. 2025 Aug;72(4):954-962. doi: 10.1002/bab.2710. Epub 2024 Dec 25. Biotechnol Appl Biochem. 2025. PMID: 39722125
-
ALKBH5 decreases SLC7A11 expression by erasing m6A modification and promotes the ferroptosis of colorectal cancer cells.Clin Transl Oncol. 2023 Jul;25(7):2265-2276. doi: 10.1007/s12094-023-03116-6. Epub 2023 Feb 23. Clin Transl Oncol. 2023. PMID: 36820954
-
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential.J Hematol Oncol. 2022 Jan 21;15(1):8. doi: 10.1186/s13045-022-01224-4. J Hematol Oncol. 2022. PMID: 35063010 Free PMC article. Review.
-
Unraveling molecular and clinical aspects of ALKBH5 as dual role in colorectal cancer.J Pharm Pharmacol. 2024 Nov 4;76(11):1393-1403. doi: 10.1093/jpp/rgae108. J Pharm Pharmacol. 2024. PMID: 39321327 Review.
Cited by
-
M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges.Front Oncol. 2025 Jul 16;15:1622359. doi: 10.3389/fonc.2025.1622359. eCollection 2025. Front Oncol. 2025. PMID: 40740874 Free PMC article. Review.
-
Integrating bulk and single-cell RNA sequencing data: unveiling RNA methylation and autophagy-related signatures in chronic obstructive pulmonary disease patients.Sci Rep. 2025 Feb 1;15(1):4005. doi: 10.1038/s41598-025-87437-2. Sci Rep. 2025. PMID: 39893187 Free PMC article.
-
Ferroptosis: Therapeutic Potential and Strategies in Non-Small Cell Lung Cancer.Biology (Basel). 2025 May 14;14(5):545. doi: 10.3390/biology14050545. Biology (Basel). 2025. PMID: 40427734 Free PMC article. Review.
-
Biological roles of enhancer RNA m6A modification and its implications in cancer.Cell Commun Signal. 2025 May 30;23(1):254. doi: 10.1186/s12964-025-02254-4. Cell Commun Signal. 2025. PMID: 40448182 Free PMC article. Review.
-
Cis-Regulation of an m6A Eraser by an Insertion Variant Associated with Survival of Patients With Non-Small Cell Lung Carcinoma.Adv Sci (Weinh). 2025 Feb;12(5):e2407652. doi: 10.1002/advs.202407652. Epub 2024 Dec 16. Adv Sci (Weinh). 2025. PMID: 39680684 Free PMC article.
References
REFERENCES
-
- Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non‐small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157:103194.
-
- Duma N, Santana‐Davila R, Molina JR. Non‐small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623‐1640.
-
- Alexander M, Kim SY, Cheng H. Update 2020: Management of non‐Small Cell Lung Cancer. Lung. 2020;198(6):897‐907.
-
- Herbst RS, Morgensztern D, Boshoff C. The biology and management of non‐small cell lung cancer. Nature. 2018;553(7689):446‐454.
-
- Bi R, Hu R, Jiang L, et al. Butyrate enhances erastin‐induced ferroptosis of lung cancer cells via modulating the ATF3/SLC7A11 pathway. Environ Toxicol. 2024;39(2):529‐538.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical